AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03901027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Conversation Interventions
Description: Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
Study NCT05037812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline
Study NCT05037812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal injections
Description: 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection).
Study NCT01257529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, low-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
Study NCT01257529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, medium-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
Study NCT01257529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, high-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
Study NCT01257529 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
Study NCT02588742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
Study NCT02588742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
Study NCT02561000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-128
Study NCT02561000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01547637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Peripheral obturator nerve block using 10 ml of 2% lidocaine
Study NCT01547637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Ultrasound guided peripheral obturator nerve block
Study NCT04134897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles
Study NCT04134897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles
Study NCT01548183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Weekly SMS assessments of risky sexual encounters with feedback
Study NCT03567330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based attachment-focused intervention
Description: 5 2-hour biweekly sessions involving parent and/or adolescent(s).
Study NCT03567330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
Study NCT00712491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Three subconjunctival injections of 1320 micrograms sirolimus each.
Study NCT00712491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Three intravitreal injections of 352 micrograms sirolimus each.
Study NCT04230785 — intervention group
Intervention type: GENETIC
Intervention: Sequencing of circRNA/lncRNA/miRNA
Description: Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
Study NCT01980082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Antibiotic
Study NCT01980082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01925378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration.
Study NCT04134897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study NCT04134897 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
Study NCT01725737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlyTI-M
Study NCT01725737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: starch
Study NCT04134897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision
Study NCT04134897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision
Study NCT04134897 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
Study NCT00207441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Self management program
Study NCT00207441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self Management Program
Study NCT01166932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Description: 100mg/Kg/day/10 days.
Study NCT01166932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone/oxacillin
Description: 75 mg/Kg/day/10 days.
Study NCT02578485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVideogame
Description: Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study NCT02578485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVideogame
Description: Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study NCT02578485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMIntensity
Description: Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study NCT02578485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EISVideogame
Description: Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study NCT02578485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study NCT04465994 — intervention group
Intervention type: PROCEDURE
Intervention: gastrocnemius turn-down flaps
Description: We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
Study NCT02731131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
Study NCT02731131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
Study NCT01141361 — intervention group
Intervention type: PROCEDURE
Intervention: GPS recording(s) of walking capacity in PAD patients
Description: Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
Study NCT05227807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mouth opening exercise
Description: The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
Study NCT01212237 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI Evaluation
Description: Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
Study NCT05227807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: routine care including written mouth exercise instructions
Study NCT04103229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of different types and volumes of solutions to inflate the catheter balloon
Description: In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
Study NCT06720194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapy
Description: Virtual therapy has been applied for four weeks, three times a week. We administered a total of twelve sessions with a duration of 30 minutes each. Prior to virtual therapy experimental group have received kinesitherapy for 15 minutes to improve and prevent muscle spasticity and joint contractures. Therapists recorded the order of the session and they have providen the same external aid to all patients. Two days a week the experimental group have received the conventional treatment for 45 minutes (kinesitherapy, strengthening exercises muscle, trunk control, transfers, standing and walking). In addition to physiotherapy treatment, participants have done occupational therapy 5 days a week (training to perform ADLs, tracking techniques and search, manipulation, reach and grasping of different utensils, etc.), for 30 minutes each session.
Study NCT06720194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual treatment
Description: Patients assigned to the control group have received the conventional treatment five days a week. They have done physiotherapy session and occupational therapy for 45 and 30 minutes a day each one.
Study NCT01410838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Broth
Description: 200 mL of sodium chloride containing broth, consumed three times per day
Study NCT01410838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Broth
Description: 200 mL of MSG containing broth consumed three times per day
Study NCT01597206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable partial denture (Chrome Cobalt Distal extension)
Description: For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
Study NCT01597206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A reduced posterior dental arch
Description: For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
Study NCT01620463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
Study NCT01620463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
Study NCT04478097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D086 Tab.
Description: 1T
Study NCT04478097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T
Study NCT01259544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Description: 300 mg of powder form dissolved in one cup of tap water prior to breath test
Study NCT01259544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Description: 300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
Study NCT02377986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIT+in-home decluterring
Description: BIT Workshop + In-home decluttering practice
Study NCT02377986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Home Decluttering
Description: In-home decluttering practice
Study NCT02919852 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic retrovesical colpopectinopexia
Description: Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
Study NCT04603989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 for Injection
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
Study NCT04603989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo , Intravenous route , multiple ascending doses
Study NCT00102388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00102388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Study NCT01971229 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Carbohydrate based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study NCT01971229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study NCT01971229 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Whey protein based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study NCT03165045 — intervention group
Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: 6 weeks
Study NCT02378142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT00333320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postconditioning
Description: patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
Study NCT01971229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study NCT03895307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: two 15 cm I type kinesio tape applied longitudinally
Study NCT03895307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: kinesio tape
Description: two 15 cm I type kinesio tape applied longitudinally
Study NCT03895307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anesthetic
Description: local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
Study NCT03895307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: local serum physiologic
Description: serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
Study NCT03355807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4
Study NCT03506425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
Study NCT01461369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg bid Capsules
Study NCT01461369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg tid Capsules
Study NCT01461369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT00963599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast/loratadine
Description: montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Study NCT00963599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: montelukast 10 mg tablet taken once daily at bed time for 2 weeks
Study NCT00963599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: loratadine
Description: loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Study NCT00963599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet taken once daily at bed time for 2 weeks
Study NCT04475068 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral Position (left and right lateral decubitus)
Description: Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
Study NCT02065973 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Study NCT01523691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated sleep restriction and recovery
Description: Repeated cycles of sleep restriction and sleep recovery
Study NCT01523691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control sleep
Description: Regular amounts of sleep across study protocol
Study NCT04442178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study NCT05266690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 2
Description: Roquette Glucidex 2: Maltodextrins with high degree of polymerization
Study NCT04442178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study NCT05135143 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant formula
Description: Administration of antioxidant formula 3 times a day and once daily.
Study NCT05266690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmacosmos Dextran 10
Description: Pharmacosmos Dextran 10: Dextran with high degree of polymerization
Study NCT05266690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 40
Description: Roquette Glucidex 40: Glucose syrup